Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 2/2024

Open Access 29-12-2023 | Bullous Pemphigoid | Review Article

Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update

Authors: Meropi Karakioulaki, Kilian Eyerich, Aikaterini Patsatsi

Published in: American Journal of Clinical Dermatology | Issue 2/2024

Login to get access

Abastract

Bullous pemphigoid (BP) is a common autoimmune bullous disease affecting mainly the elderly, with rising incidence due to increased life expectancy. This disease is characterized by tense bullous lesions on normal or erythematous skin, accompanied by pruritus. BP pathogenesis involves autoantibodies against hemidesmosomal proteins BP180 and BP230, leading to detachment at the dermo-epidermal junction as well as blister formation. BP is associated with coexisting comorbidities and drug exposure, and its management often requires high doses or chronic use of systemic glucocorticoids, posing risks of adverse effects. This review focuses on novel treatment options for BP, exploring therapies targeting different immune pathways. Rituximab, a CD20 monoclonal antibody, depletes B-lymphocytes and has shown efficacy in severe cases. Dupilumab, targeting interleukin (IL)-4 receptor α and thus blocking IL-4 and IL-13, downregulates type 2 helper (Th2) responses and has demonstrated promising results. Targeting eosinophil-related molecules using bertilimumab and AKST4290 has yielded positive results in clinical trials. Omalizumab, an immunoglobulin (Ig) E antibody, can reduce disease severity and allows corticosteroid tapering in a number of cases. Complement inhibitors such as nomacopan and avdoralimab are being investigated. IL-17 and IL-23 inhibitors such as secukinumab and tildrakizumab have shown potential in a limited number of case reports. Neonatal Fc receptor antagonists such as efgartigimod are under investigation. Additionally, topical therapies and Janus kinase inhibitors are being explored as potential treatments for BP. These novel therapies offer promising alternatives for managing BP, with potential to improve outcomes and reduce high cumulative doses of systemic corticosteroids and related toxicities. Further research, including controlled clinical trials, is needed to establish their efficacy, safety, and optimal dosing regimens for BP management.
Literature
1.
van Beek N, et al. IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases. Expert Rev Clin Immunol. 2016;12(3):267–77.PubMedCrossRef
2.
3.
4.
Kridin K, Shihade W, Bergman R. Mortality in patients with bullous pemphigoid: a retrospective cohort study, systematic review and meta-analysis. Acta Derm Venereol. 2019;99(1):72–7.PubMed
5.
Kridin K, et al. Mortality in bullous pemphigoid: a systematic review and meta-analysis of standardized mortality ratios. J Dermatol. 2018;45(9):1094–100.PubMedCrossRef
6.
7.
8.
Chai ZT, et al. Diabetes mellitus and hyperglycemic complications in bullous pemphigoid. J Am Acad Dermatol. 2020;82(5):1234–7.PubMedCrossRef
9.
Kibsgaard L, et al. Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid. Br J Dermatol. 2017;176(6):1486–91.PubMedCrossRef
10.
Lee S, et al. Association of bullous pemphigoid and comorbid health conditions: a case-control study. Arch Dermatol Res. 2021;313(5):327–32.PubMedCrossRef
11.
Baum, S., et al., Prevalence, Spectrum and Clinical Implications of Malignancies in Patients with Bullous Pemphigoid. Acta Derm Venereol, 2023. 103:adv00888.
12.
Salemme A, et al. Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study. J Am Acad Dermatol. 2022;87(1):56–63.PubMedCrossRef
13.
14.
Afarideh M, Borucki R, Werth VP. A review of the immunologic pathways involved in bullous pemphigoid and novel therapeutic targets. J Clin Med. 2022;11(10):2856.PubMedPubMedCentralCrossRef
15.
Kasperkiewicz M, et al. COVID-19 pandemic and autoimmune bullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation. J Eur Acad Dermatol Venereol. 2021;35(7):e418–21.PubMedPubMedCentralCrossRef
16.
Maronese CA, et al. Bullous pemphigoid associated with COVID-19 vaccines: an Italian Multicentre Study. Front Med (Lausanne). 2022;9: 841506.PubMedCrossRef
17.
Kasperkiewicz M, Zillikens D. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol. 2007;33(1–2):67–77.PubMedCrossRef
18.
19.
20.
Schmidt E, et al. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol. 2000;136(2):174–8.PubMedCrossRef
21.
Iwata Y, et al. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol. 2008;144(1):41–8.PubMedCrossRef
22.
Zhang L, et al. Bullous pemphigoid: The role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy. Front Immunol. 2023;14:1115083.PubMedPubMedCentralCrossRef
23.
Saniklidou AH, et al. IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review. Arch Dermatol Res. 2018;310(1):11–28.PubMedCrossRef
24.
Rice JB, et al. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017;39(11):2216–29.PubMedCrossRef
25.
Joly P, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321–7.PubMedCrossRef
26.
Feliciani C, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol. 2015;172(4):867–77.PubMedCrossRef
27.
Zeng FAP, et al. Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: a systematic review. JAAD Int. 2022;9:33–43.PubMedPubMedCentralCrossRef
28.
Bystryn JC. Comparative effectiveness of azathioprine or mycophenolate mofetil as an adjuvant for the treatment of bullous pemphigoid. Arch Dermatol. 2008;144(7):946.PubMedCrossRef
29.
Fivenson DP, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol. 1994;130(6):753–8.PubMedCrossRef
30.
Wojtczak M, et al. Can methotrexate be employed as monotherapy for bullous pemphigoid? Analysis of efficiency and tolerance of methotrexate treatment in patients with bullous pemphigoid. J Clin Med. 2023;12(4):1638.PubMedPubMedCentralCrossRef
31.
Du-Thanh A, et al. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. Br J Dermatol. 2011;165(6):1337–43.PubMedCrossRef
32.
Bouscarat F, et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol. 1996;34(4):683–4.PubMedCrossRef
33.
Barthelemy H, et al. Cyclosporin in the treatment of bullous pemphigoid: preliminary study. Ann Dermatol Venereol. 1986;113(4):309–13.PubMed
34.
Kremer N, et al. Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature. Am J Clin Dermatol. 2019;20(2):209–16.PubMedCrossRef
35.
Garrido PM, et al. Emerging treatments for bullous pemphigoid. J Dermatolog Treat. 2022;33(2):649–61.PubMedCrossRef
36.
Huang H, Benoist C, Mathis D. Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci U S A. 2010;107(10):4658–63.PubMedPubMedCentralCrossRefADS
37.
Thomas RM, Colon A, Motaparthi K. Rituximab in autoimmune pemphigoid diseases: indications, optimized regimens, and practice gaps. Clin Dermatol. 2020;38(3):384–96.PubMedCrossRef
38.
Amber KT, et al. Targeted therapies for autoimmune bullous diseases: current status. Drugs. 2018;78(15):1527–48.PubMedCrossRef
39.
Berkani N, et al. B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid. Sci Rep. 2019;9(1):3525.PubMedPubMedCentralCrossRefADS
40.
Polansky M, et al. Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients. J Am Acad Dermatol. 2019;81(1):179–86.PubMedCrossRef
41.
Tovanabutra N, Payne AS. Clinical outcome and safety of rituximab therapy for pemphigoid diseases. J Am Acad Dermatol. 2020;82(5):1237–9.PubMedCrossRef
42.
Hall RP 3rd, et al. Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients. J Invest Dermatol. 2013;133(12):2786–8.PubMedCrossRef
43.
44.
45.
Chiorean RM, et al. Complement-activating capacity of autoantibodies correlates with disease activity in bullous pemphigoid patients. Front Immunol. 2018;9:2687.PubMedPubMedCentralCrossRef
46.
Wallet-Faber N, et al. Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab. Dermatology. 2007;215(3):252–5.PubMedCrossRef
47.
Chen Q, et al. Three cases of refractory bullous pemphigoid in the elderly treated successfully with ultra-low-dose rituximab. J Dermatol. 2023;50(4):561–4.PubMedCrossRef
48.
Suarez-Carantona C, et al. Low-dose rituximab for bullous pemphigoid. Protocol and single-center experience. Actas Dermosifiliogr. 2023;114(1):T62–8.PubMedCrossRef
49.
Cho YT, Chu CY, Wang LF. First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid. Br J Dermatol. 2015;173(1):302–4.PubMedCrossRef
50.
Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 2015;135(3):626–35.PubMedCrossRef
51.
52.
53.
Fang H, Li Q, Wang G. The role of T cells in pemphigus vulgaris and bullous pemphigoid. Autoimmun Rev. 2020;19(11): 102661.PubMedCrossRef
54.
Tavakolpour S. Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus. Dermatol Ther. 2016;29(5):299.PubMedCrossRef
55.
Takamura S, Teraki Y. Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primarily suppressing T-helper 2 cytokines. J Dermatol. 2022;49(9):845–50.PubMedCrossRef
56.
Feliciani C, et al. A Th2-like cytokine response is involved in bullous pemphigoid. The role of IL-4 and IL-5 in the pathogenesis of the disease. Int J Immunopathol Pharmacol. 1999;12(2):55–61.PubMedCrossRef
57.
Giomi B, et al. Th1, Th2 and Th3 cytokines in the pathogenesis of bullous pemphigoid. J Dermatol Sci. 2002;30(2):116–28.PubMedCrossRef
58.
59.
60.
61.
Gounni Abdelilah S, et al. Increased expression of Th2-associated chemokines in bullous pemphigoid disease. Role of eosinophils in the production and release of these chemokines. Clin Immunol. 2006;120(2):220–31.PubMedCrossRef
62.
Gooderham MJ, et al. Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78(3 Suppl 1):S28–36.PubMedCrossRef
63.
Abdat R, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol. 2020;83(1):46–52.PubMedCrossRef
64.
Yang J, et al. Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid. Dermatol Ther. 2022;35(8): e15648.PubMedCrossRef
65.
66.
Seyed Jafari SM, et al. Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid. Front Immunol. 2020;11: 611549.PubMedCrossRef
67.
Bruni M, et al. A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab. Dermatol Online J. 2022;28(2).
68.
69.
Zhao L, et al. Evaluation of dupilumab in patients with bullous pemphigoid. JAMA Dermatol. 2023;159(9):953–60.PubMedCrossRef
70.
US National Library of Medicine, ClinicalTrials.gov. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid, NCT04206553. 2019. Available at: https://​clinicaltrials.​gov/​ct2/​show/​NCT04206553.
71.
Pruessmann J, et al. Immunomodulator galectin-9 is increased in blood and skin of patients with bullous pemphigoid. Acta Derm Venereol. 2021;101(3):adv00419.PubMedCrossRef
72.
Engmann J, et al. increased activity and apoptosis of eosinophils in blister fluids, skin and peripheral blood of patients with bullous pemphigoid. Acta Derm Venereol. 2017;97(4):464–71.PubMedCrossRef
73.
Gore Karaali M, et al. Tissue eosinophil levels as a marker of disease severity in bullous pemphigoid. Australas J Dermatol. 2021;62(2):e236–41.PubMedCrossRef
74.
Kridin K. Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation. Br J Dermatol. 2018;179(5):1141–7.PubMedCrossRef
75.
76.
77.
Frezzolini A, et al. Increased expression of eotaxin and its specific receptor CCR3 in bullous pemphigoid. Eur J Dermatol. 2002;12(1):27–31.PubMed
78.
Shrikhande M, et al. Increased coexpression of eotaxin and interleukin 5 in bullous pemphigoid. Acta Derm Venereol. 2000;80(4):277–80.PubMedCrossRef
79.
Wakugawa M, et al. Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia. Br J Dermatol. 2000;143(1):112–6.PubMedCrossRef
80.
Gunther C, et al. Up-regulation of CCL11 and CCL26 is associated with activated eosinophils in bullous pemphigoid. Clin Exp Immunol. 2011;166(2):145–53.PubMedPubMedCentralCrossRef
81.
Amber KT, et al. Mechanisms of pathogenic effects of eosinophil cationic protein and eosinophil-derived neurotoxin on human keratinocytes. Exp Dermatol. 2018;27(12):1322–7.PubMedCrossRef
82.
83.
84.
Okada S, et al. Transmigration of eosinophils through basement membrane components in vitro: synergistic effects of platelet-activating factor and eosinophil-active cytokines. Am J Respir Cell Mol Biol. 1997;16(4):455–63.PubMedCrossRef
85.
Rudrich U, et al. Eosinophils are a major source of interleukin-31 in bullous pemphigoid. Acta Derm Venereol. 2018;98(8):766–71.PubMedCrossRef
86.
87.
88.
89.
Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science. 1997;277(5334):2005–7.PubMedCrossRef
90.
Stirling RG, et al. Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. Am J Respir Crit Care Med. 2001;164(8 Pt 1):1403–9.PubMedCrossRef
91.
D’Auria L, et al. IL-5 levels in the serum and blister fluid of patients with bullous pemphigoid: correlations with eosinophil cationic protein, RANTES, IgE and disease severity. Arch Dermatol Res. 1998;290(1–2):25–7.PubMedCrossRef
92.
Bettiol A, et al. Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study. Arthritis Rheumatol. 2022;74(2):295–306.PubMedCrossRef
93.
Han JK, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141–53.PubMedCrossRef
94.
Ortega HG, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–207.PubMedCrossRef
95.
Pavord ID, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–9.PubMedCrossRef
96.
97.
Simon D, et al. Mepolizumab failed to affect bullous pemphigoid: a randomized, placebo-controlled, double-blind phase 2 pilot study. Allergy. 2020;75(3):669–72.PubMedCrossRef
98.
Castro M, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–66.PubMedCrossRef
99.
100.
101.
Rhyou HI, Han SH, Nam YH. Successful induction treatment of bullous pemphigoid using reslizumab: a case report. Allergy Asthma Clin Immunol. 2021;17(1):117.PubMedPubMedCentralCrossRef
102.
Bagnasco D, et al. Anti-interleukin 5 (IL-5) and IL-5Ra biological drugs: efficacy, safety, and future perspectives in severe eosinophilic asthma. Front Med (Lausanne). 2017;4:135.PubMedCrossRef
103.
FitzGerald JM, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–41.PubMedCrossRef
104.
105.
Dresow SK, et al. IgE autoantibodies against the intracellular domain of BP180. Br J Dermatol. 2009;160(2):429–32.PubMedCrossRef
106.
Provost TT, Tomasi Jr. TB. Immunopathology of bullous pemphigoid Basement membrane deposition of IgE, alternate pathway components and fibrin. Clin Exp Immunol. 1974;18(2):193–200.PubMedPubMedCentral
107.
Messingham KA, et al. Functional characterization of an IgE-class monoclonal antibody specific for the bullous pemphigoid autoantigen, BP180. Hybridoma (Larchmt). 2012;31(2):111–7.PubMedCrossRef
108.
Kalowska M, et al. Enzyme-linked immunoassay index for anti-NC16a IgG and IgE auto-antibodies correlates with severity and activity of bullous pemphigoid. Acta Derm Venereol. 2016;96(2):191–6.PubMedCrossRef
109.
Kamata A, et al. Basement membrane zone IgE deposition is associated with bullous pemphigoid disease severity and treatment results. Br J Dermatol. 2020;182(5):1221–7.PubMedCrossRef
110.
van Beek N, et al. Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity. JAMA Dermatol. 2017;153(1):30–8.PubMedCrossRef
111.
Fania L, et al. IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses. Clin Immunol. 2012;143(3):236–45.PubMedCrossRef
112.
Hashimoto T, et al. Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid. Br J Dermatol. 2017;177(1):141–51.PubMedCrossRef
113.
Cozzani E, et al. Anti-230 kDa circulating IgE in bullous pemphigoid: relationship with disease activity. Acta Derm Venereol. 1997;77(3):236.PubMedCrossRef
114.
Ishiura N, et al. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci. 2008;49(2):153–61.PubMedCrossRef
115.
Shih YC, et al. BP230 IgE autoantibodies in topical-steroid-resistant bullous pemphigoid. J Dermatol. 2021;48(9):1372–80.PubMedCrossRef
116.
117.
Balakirski G, et al. Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature. J Eur Acad Dermatol Venereol. 2016;30(10):1778–82.PubMedCrossRef
118.
James T, et al. IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid. Clin Immunol. 2019;198:54–6.PubMedCrossRef
119.
120.
Sarrazin M, Jouen F, Duvert-Lehembre S. Refractory bullous pemphigoid with IgE anti-BP230 and IgG anti-p200 antibodies successfully treated with omalizumab. Ann Dermatol Venereol. 2021;148(1):60–2.PubMedCrossRef
121.
De D, et al. Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co-morbidities. J Eur Acad Dermatol Venereol. 2021;35(7):e469–72.PubMedCrossRef
122.
Gonul MZ, et al. Bullous pemphigoid successfully treated with omalizumab. Indian J Dermatol Venereol Leprol. 2016;82(5):577–9.PubMedCrossRef
123.
London VA, et al. Successful treatment of bullous pemphigoid with omalizumab. Arch Dermatol. 2012;148(11):1241–3.PubMedCrossRef
124.
Dufour C, et al. Successful management of severe infant bullous pemphigoid with omalizumab. Br J Dermatol. 2012;166(5):1140–2.PubMedCrossRef
125.
Maglie R, et al. Dramatic exacerbation of bullous pemphigoid following rituximab and successful treatment with omalizumab. Eur J Dermatol. 2019;29(2):213–5.PubMedCrossRef
126.
127.
Chebani R, et al. Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients. Br J Dermatol. 2023;ljad369.
128.
Garrido PM, et al. Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid efficiently treated with omalizumab. Dermatol Ther. 2020;33(6): e14160.PubMedCrossRef
129.
Vico-Alonso C, et al. Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: a case report. Dermatol Ther. 2019;32(2): e12829.PubMedCrossRef
130.
131.
Beek NV, Zillikens D, Schmidt E. Bullous Autoimmune Dermatoses-Clinical Features, Diagnostic Evaluation, and Treatment Options. Dtsch Arztebl Int. 2021;118(24):413–20.PubMedPubMedCentral
132.
Iwata H, Kitajima Y. Bullous pemphigoid: role of complement and mechanisms for blister formation within the lamina lucida. Exp Dermatol. 2013;22(6):381–5.PubMedCrossRef
133.
Lessey E, et al. Complement and cutaneous autoimmune blistering diseases. Immunol Res. 2008;41(3):223–32.PubMedCrossRef
134.
Sadik CD, et al. The critical role of C5a as an initiator of neutrophil-mediated autoimmune inflammation of the joint and skin. Semin Immunol. 2018;37:21–9.PubMedCrossRef
135.
Sezin T, et al. Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease. JCI Insight. 2019;4(15):e128239.PubMedPubMedCentralCrossRef
136.
DiScipio RG, Schraufstatter IU. The role of the complement anaphylatoxins in the recruitment of eosinophils. Int Immunopharmacol. 2007;7(14):1909–23.PubMedCrossRef
137.
Zeck-Kapp G, et al. Mechanisms of human eosinophil activation by complement protein C5a and platelet-activating factor: similar functional responses are accompanied by different morphologic alterations. Allergy. 1995;50(1):34–47.PubMedCrossRef
138.
139.
Mihai S, et al. Specific inhibition of complement activation significantly ameliorates autoimmune blistering disease in mice. Front Immunol. 2018;9:535.PubMedPubMedCentralCrossRef
140.
Sadik CD, et al. Evaluation of nomacopan for treatment of bullous pemphigoid: a phase 2a nonrandomized controlled trial. JAMA Dermatol. 2022;158(6):641–9.PubMedPubMedCentralCrossRef
141.
142.
143.
Freire, P.C., et al., Specific Inhibition of the Classical Complement Pathway Prevents C3 Deposition along the Dermal-Epidermal Junction in Bullous Pemphigoid. J Invest Dermatol, 2019. 139(12):2417-2424 e2.
144.
Dias PM, Banerjee G. The role of Th17/IL-17 on eosinophilic inflammation. J Autoimmun. 2013;40:9–20.PubMedCrossRef
145.
Holtsche MM, et al. Adjuvant treatment with secukinumab induced long term remission in a patient with severe bullous pemphigoid. J Dtsch Dermatol Ges. 2020;18(12):1478–80.PubMed
146.
Kamata M, et al. Secukinumab decreased circulating anti-BP180-NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid. J Dermatol. 2019;46(6):e216–7.PubMedCrossRef
147.
Yun JS, et al. Successful secukinumab treatment of active bullous pemphigoid and chronic severe psoriasis: a case report. Australas J Dermatol. 2022;63(2):e155–8.PubMedCrossRef
148.
Ho PH, Tsai TF. Development of bullous pemphigoid during secukinumab treatment for psoriasis. J Dermatol. 2017;44(9):e220–1.PubMedCrossRef
149.
150.
151.
152.
153.
Delli FS, et al. Total IgE, eosinophils, and interleukins 16, 17A, and 23 correlations in severe bullous pemphigoid and treatment implications. Dermatol Ther. 2020;33(6): e13958.PubMedCrossRef
154.
Plee J, et al. Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome. Sci Rep. 2015;5:18001.PubMedPubMedCentralCrossRefADS
155.
156.
Cole C, Amber KT. Two patients with concomitant bullous pemphigoid and psoriasis successfully treated by IL-23 inhibition. J Eur Acad Dermatol Venereol. 2023;37(11):e1339–40.PubMedCrossRef
157.
Majima Y, et al. A successful treatment with ustekinumab in a case of antilaminin-gamma1 pemphigoid associated with psoriasis. Br J Dermatol. 2013;168(6):1367–9.PubMedCrossRef
158.
Loget J, et al. A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):e228–30.PubMedCrossRef
159.
Marin M, et al. Bullous pemphigoid induced by ustekinumab: a case report. Eur J Hosp Pharm. 2021;28(1):47–9.PubMedCrossRef
160.
161.
162.
163.
Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A. 1996;93(11):5512–6.PubMedPubMedCentralCrossRefADS
164.
165.
166.
Fang H, et al. Increased expression of NLRP3 inflammasome components and interleukin-18 in patients with bullous pemphigoid. J Dermatol Sci. 2016;83(2):116–23.PubMedCrossRef
167.
168.
169.
Nash D, Kirchhof MG. Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib. JAAD Case Rep. 2023;32:81–3.PubMedCrossRef
170.
Xiao Y, Xiang H, Li W. Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib. Dermatol Ther. 2022;35(10): e15754.PubMedCrossRef
171.
Li H, et al. Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: a case report and review of the literature. Int Immunopharmacol. 2023;122: 110591.PubMedCrossRef
172.
Maglie R, et al. The cytokine milieu of bullous pemphigoid: Current and novel therapeutic targets. Front Med (Lausanne). 2023;10:1128154.PubMedCrossRef
Metadata
Title
Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update
Authors
Meropi Karakioulaki
Kilian Eyerich
Aikaterini Patsatsi
Publication date
29-12-2023
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 2/2024
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-023-00832-1

Other articles of this Issue 2/2024

American Journal of Clinical Dermatology 2/2024 Go to the issue

Original Research Article

Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year

Original Research Article

Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

Review Article

Pressure and Skin: A Review of Disease Entities Driven or Influenced by Mechanical Pressure

Review Article

Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors

Leading Article

The Skin Microbiome and its Significance for Dermatologists

Review Article

Mucocutaneous Manifestations of Recreational Drug Use